NanoBio Corporation,
a privately held biopharmaceutical company focused on developing and commercializing
dermatological products, anti-infective treatments and intranasal vaccines derived
from its patented NanoStat™ technology platform, today announced compelling
preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills
highly drug-resistant strains of bacteria commonly found in cystic fibrosis
patients. Currently there are limited treatment options available that effectively
address these resistant bacteria. The study results are being presented today
at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis,
Minn.
“Given that cystic fibrosis patients are susceptible to respiratory failure
following repeated bacterial infections of the lung, there is a tremendous need
to develop new treatments that can overcome drug-resistant bacteria,”
said James R. Baker, Jr., MD, NanoBio’s CEO and founder. “In laboratory
studies, NB-401 is a very potent killer against these difficult strains.”
NB-401 has been shown to be highly efficacious in vitro against Pseudomonas
aeruginosa, Burkholderia, Acinetobacter, Stenotrophomonas and other multidrug-resistant
bacterial strains from cystic fibrosis (CF) patients, including colistin-resistant
isolates of Burkholderia and Stenotrophomonas. In addition, the nanoemulsion
is effective against organisms that are grown in biofilm and the sputum from
CF patients. Resistance to the nanoemulsion is not anticipated based on its
unique mechanism of action of interacting with the bacterial membrane and causing
physical lysis of the organism.
These findings suggest that the use of NB-401 may have clinical benefit in
treating CF patients. NanoBio has completed additional studies demonstrating
that NB-401 can effectively be nebulized for the treatment of pulmonary infections.
The company is currently conducting toxicity studies prior to advancing to clinical
testing of NB-401 for the treatment of bacterial infections associated with
cystic fibrosis.
Cystic fibrosis affects an estimated 30,000 individuals in the United States
and a total of 70,000 people worldwide.
About NanoBio
NanoBio® Corp. is a privately held biopharmaceutical company focused on
developing and commercializing dermatological products, anti-infective treatments
and intranasal vaccines derived from its patented NanoStat™ technology
platform. The company’s lead product candidates are treatments for herpes
labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and
a broad platform of intranasal vaccines. The company’s headquarters and
laboratory facilities are located in Ann Arbor, Michigan.
Posted October 15th, 2009
